Global

Obesity treatment is becoming a portfolio, not a product. Lilly’s EASD lineup shows what comes next

Medical AI can ace the benchmark and still fail the clinic. Real-world evidence is the next test

RAS Has Finally Hit Pancreatic Cancer. Now Access Has to Catch Up.

Polycythemia Vera Gets a First-in-Class Option. Patients Need More Than Blood Draws.

Cardiovascular AI is getting better. That does not mean it is getting fairer

HER2 Testing Just Became the Gatekeeper in Gastroesophageal Cancer

MS Gets a Cleaner BTK Signal

Mpox Finally Gets A Stockpile

Brain Tumour Surgery Is Getting Smaller. Access Cannot Stay Elite.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
